Magnolia Oil & Gas Corporation Class A Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Magnolia Oil & Gas Corporation Class A Common Stock trades at $24.82 (market cap $6.76B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is the larger of the two by market cap, and Magnolia Oil & Gas Corporation Class A Common Stock pays a 2.63% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Magnolia Oil & Gas Corporation Class A Common Stock for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| MGY | PCVX | |
|---|---|---|
Market Cap | $6.76B | $10.51B |
Volume | 2,815,157 | 2,644,694 |
Sector | Energy | Health |
52-Week High | $32.36 | $73.82 |
52-Week Low | $21.24 | $40.32 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $6.88B | $9.14B |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Magnolia Oil & Gas (MGY) trades at $25.11, up 2.66% with neutral technical signals. The company demonstrates strong fundamentals with a P/E of 10.97, net income margin of 28.77%, and consistent earnings beats. Recent WildFire Energy acquisition positions MGY for production doubling and significant free cash flow growth, with 2027 FCF projected over $1 billion. Analyst consensus remains strongly bullish with 66.7% buy ratings and $33.78 price target.
MGY presents compelling value with attractive valuation multiples and robust profitability metrics. The WildFire acquisition accelerates growth but introduces integration execution risk. Current price offers 35% upside to consensus target, though oil price volatility and operational execution remain key watchpoints for investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Magnolia Oil & Gas Corporation is an independent oil and gas exploration and production company operating in the Eagle Ford Shale and Austin Chalk formations of South Texas.
Read more on MGY →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →